Nielsen, Cecilie Marie http://orcid.org/0000-0002-7319-5115
Kølbæk, Pernille
Dines, David http://orcid.org/0000-0003-4140-6763
Opler, Mark
Correll, Christoph U.
Østergaard, Søren Dinesen http://orcid.org/0000-0002-8032-6208
Funding for this research was provided by:
Det Frie Forskningsråd (7016-00048B, 701600048B, 701600048B, 701600048B, 701600048B, 701600048B)
Article History
Received: 22 May 2023
Accepted: 4 July 2023
First Online: 31 August 2023
Competing interests
: C.M.N. owns units of mutual funds with stock tickers SPVIGAKL and SPVIGAETIK. D.D. has received financial support from Lundbeck to cover expenses for travel/accomodation in relation to conference participation. M.O. is an employee and shareholder of WCG Inc. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. S.D.Ø. received the 2020 Lundbeck Foundation Young Investigator Prize. Furthermore, S.D.Ø. owns/has owned units of mutual funds with stock tickers DKIGI, IAIMWC and WEKAFKI, and has owned units of exchange traded funds with stock tickers BATE, TRET, QDV5, QDVH, QDVE, SADM, IQQH, USPY, EXH2, 2B76 and EUNL. The remaining authors declare no conflicts of interest.